EUR/USD likely to find a peak near 1.25: UBS
Tuesday, H.C. Wainwright reaffirmed its Buy rating and $90.00 price target for Insmed shares (NASDAQ:INSM), which has delivered an impressive 188% return over the past year. The stock, currently trading at $69.51, has analyst targets ranging from $89 to $110, according to InvestingPro data. The research firm’s analyst, Andrew Fein, emphasized the potential of Brensocatib for treating bronchiectasis in patients with Alpha-1 antitrypsin deficiency (AATD), a condition that has a prevalence of 21% to 36% among those diagnosed, according to a study published in COPD in 2024.
The reiteration of the Buy rating follows insights gained from the Alpha One Foundation’s 7th Global Research Conference in Lisbon, Portugal, where discussions highlighted the clinical significance of bronchiectasis within the AATD population. Fein noted that bronchiectasis occurs independently of Chronic Obstructive Pulmonary Disease (COPD) in a significant minority of AATD patients and is linked to severe symptoms like shortness of breath.
The conference also underscored the importance of screening for bronchiectasis, especially in patients with emphysema, to ensure appropriate treatment. A study by Alice Turner’s group at the University of Birmingham was mentioned, which investigated the rates, radiological appearance, and severity of bronchiectasis in a large AATD patient database. The study aimed to determine whether the condition is associated with COPD or exists independently and to assess its impact on disease outcomes such as lung function decline, exacerbation rate, and symptoms.
Fein’s commentary highlighted a growing consensus on the need for AATD screening in bronchiectasis patients and the critical nature of proper treatment for bronchiectasis. This understanding supports the ongoing interest and potential for Brensocatib as a treatment option for AATD-associated bronchiectasis. The analyst’s reiterated Buy rating and price target reflect confidence in the therapeutic prospects of Brensocatib and its relevance to the AATD community. With a market capitalization of $12.64 billion and revenue growth of 19.17%, Insmed shows strong financial fundamentals, maintaining a healthy current ratio of 5.45. For deeper insights into Insmed’s valuation and growth potential, access the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of the company’s financial health and market position.
In other recent news, Insmed has been the focus of various analyst reports highlighting developments in its drug pipeline. Cantor Fitzgerald reiterated an Overweight rating for Insmed, expressing optimism about the company’s Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) due to its potential for more convenient dosing and improved patient adherence. Meanwhile, H.C. Wainwright maintained a Buy rating with a $90 price target, following Insmed’s presentation at the 2025 Annual MDA Conference on a novel gene therapy for Duchenne muscular dystrophy (DMD), which showed promising results in preclinical studies. RBC Capital Markets also reaffirmed their Outperform rating with a $100 price target, citing confidence in TPIP’s expected performance in improving pulmonary vascular resistance and walk distance, which could support a significant market opportunity.
Truist Securities maintained a Buy rating and a $108 price target, projecting a favorable risk/reward outlook for Insmed’s upcoming TPIP data and the potential commercial launch of brensocatib. UBS raised its price target for Insmed to $110, maintaining a Buy rating, based on expectations for Phase 2 data for TPIP in PAH. UBS emphasized the significance of achieving a meaningful reduction in pulmonary vascular resistance, which could position TPIP as a leading treatment option. These recent developments highlight the anticipation surrounding Insmed’s drug candidates and their potential impact on the treatment landscape for serious diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.